MCM
PYXS icon

Mainstream Capital Management’s Pyxis Oncology PYXS Stock Holding History

Mainstream Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$312 – 241
2024
Q4 		$312 Buy
+200
New +$577 ﹤0.01% 315

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Mainstream Capital Management's PYXS Position: Q1 2025 in Review

Mainstream Capital Management sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 200 shares — an estimated $312 sold.

Mainstream Capital Management first reported a position in PYXS in Q4 2024 and held it in 1 quarter. The position peaked at $312 in Q4 2024. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

  • Mainstream Capital Management reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
  • Mainstream Capital Management sold 200 Pyxis Oncology shares in Q1 2025, an estimated $312.
  • Mainstream Capital Management first reported a position in Pyxis Oncology in Q4 2024 and held it in 1 quarter.
  • Mainstream Capital Management's Pyxis Oncology position peaked at $312 in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on Mainstream Capital Management's 13F filing for Q1 2025, filed 28 Apr 2025.